A new research paper was published in Volume 18 of Aging-US on February 8, 2026, titled "Single-cell transcriptomics reveal ...
Multiple myeloma is a cancer that occurs when a type of white blood cell grows out of control, causing low blood counts, bone and calcium problems, frequent infections and kidney damage. According to ...
A recent publication in Nature Medicine describes a novel immunotherapy targeting pancreatic cancer that has shown promising results in a first in-human phase 1/2 trial. The TACTOPS trial, which ...
CD7 is an attractive target for chimeric antigen receptor (CAR) T-cell therapy in relapsed or refractory T-cell acute lymphoblastic leukemia (ALL). Supportive results of first-in-human studies of base ...
INB-619 demonstrated equivalent efficacy to the FDA approved, commercial T Cell Engagers (TCE) compounds, blinatumomab and mosunetuzumab, with minimal adverse cytokine release, highlighting a targeted ...
CAR T therapy improves survival in B-cell malignancies but presents toxicities like CRS, ICANS, ICAHT, and IEC-HS, requiring careful management. ICAHT is classified into early and late phases, with ...
CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, today announced new paradigm changing findings from the Phase 2 QUILT-3.055 study, ...
People living with chronic HIV (PLWH) show immune dysfunction, despite viral suppression and normal CD4 recovery, particularly those with low CD4/CD8 ratios. Subjacent cellular alterations of such a ...
Low HLA-DR+CD3+ T cell counts correlate with increased TRM and severe cGVHD post-HSCT, especially in RIC patients. Ideal predictive cutoff for absolute T cell counts is 140 cells/μL, with significant ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results